Drug intelligence / Profile preview

ADB-158

Development stage: Preclinical
Lead developer: AdaptBio Therapeutics
Modality: Vaccines & Immunotherapeutics

Overview

**ADB-158** is a discovery-stage, tumor-directed vaccine program from AdaptBio Therapeutics for **HER2-positive breast cancer** and **metastatic gastric cancer**. It is described as a novel dual-epitope combination immunotherapy intended to generate antitumor immune responses against HER2 and HER3 while incorporating PD-1 and VEGF as reported immunologic and angiogenic targets. Publicly available source material does not specify the vaccine construct, epitopes, adjuvant, dosage form, route of administration, or the exact functional role of each listed target.

Targets

PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFA (Vascular endothelial growth factor A)ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on ADB-158.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB-158.

Explore the full profile